Retatrutide in Pediatric Patients Under 12: What Happens at the Transition to Adult Care

What Is Retatrutide and Why Does It Matter for Young Patients

Retatrutide (LY3437943) is a single peptide that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCGR) receptor. That triple mechanism produces larger weight reduction than any currently approved GLP-1 monotherapy in adult trials. Phase 2 data published in the New England Journal of Medicine showed a mean body-weight reduction of 24.2% at 48 weeks with the 12 mg dose versus 2.1% with placebo in adults with obesity [1].

Pediatric obesity is a serious and growing public health issue. The CDC reports that 19.7% of U.S. Children and adolescents aged 2 to 19 years have obesity, representing roughly 14.7 million young people [2]. Severe obesity in childhood is linked to early-onset type 2 diabetes, non-alcoholic fatty liver disease, obstructive sleep apnea, and cardiovascular risk factors that persist into adulthood [3].

Why Retatrutide Is Not Yet Standard for Children Under 12

The FDA has not approved retatrutide for adults or children. Eli Lilly's Phase 3 TRIUMPH program is ongoing in adults. No published pediatric trial exists specifically for children under 12 as of July 2025. The closest approved comparator for younger adolescents is semaglutide 2.4 mg (Wegovy), cleared by FDA in December 2022 for patients aged 12 and older with a BMI at or above the 95th percentile [4].

Children under 12 occupy a regulatory and clinical gray zone. Prescribing retatrutide in this age group would constitute off-label use, carrying substantial liability and ethical obligations for the treating clinician.

The Biological Case for Eventual Pediatric Study

Triple receptor agonism may be particularly relevant in children with severe obesity driven by hyperphagia, such as those with monogenic obesity disorders. Research into MC4R deficiency and POMC pathway mutations has identified populations where GLP-1 receptor engagement alone produces partial responses [5]. Retatrutide's additional glucagon receptor activity raises caloric expenditure beyond what GLP-1 agonism alone achieves, a mechanism that may benefit patients who do not fully respond to approved agents.

The Regulatory Field as of Mid-2025

FDA Pediatric Study Requirements

Under the Pediatric Research Equity Act (PREA), sponsors are generally required to conduct pediatric studies for drugs that are likely to be used in the pediatric population. The FDA's pediatric study plans for retatrutide have not been publicly released at the completion level that would indicate an approved plan for children under 12. Lilly's Pediatric Study Plan (iPSP) submissions are reviewed by the FDA's Office of Pediatric Therapeutics, and any approval for children would require separate safety and efficacy data [6].

What Approvals Exist for Comparable Drugs in Children

Liraglutide 3 mg (Saxenda) received FDA approval for obesity treatment in adolescents aged 12 and older in 2020. Semaglutide 2.4 mg (Wegovy) followed in December 2022 for the same age band. Phentermine-topiramate (Qsymia) earned approval down to age 12 in 2022. No anti-obesity pharmacotherapy currently carries FDA approval below age 12 for obesity treatment, reinforcing that retatrutide's use in this population would be well outside approved indications [4].

The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity states: "Clinicians should offer adolescents 12 years and older with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment." The guideline does not recommend pharmacotherapy for children under 12 as standard care [7].

Transition to Adult Care: Why It Is Clinically Complex

Care transitions for any chronic condition carry risk of treatment discontinuation, loss to follow-up, and worsening of the underlying condition. For pediatric patients on investigational or off-label anti-obesity pharmacotherapy, these risks multiply.

Defining the Transition Window

Most pediatric endocrinology programs transfer patients to adult care between ages 18 and 21, though some institutions begin the handoff process at 16. The Society for Adolescent Health and Medicine recommends a structured transition beginning no later than age 14, with formal transfer by age 18 [8]. A young patient who starts retatrutide off-label at age 10 or 11 will cross this transition boundary while still mid-course in what is intended to be a long-term therapy.

What the Evidence Says About Transition Failures in Obesity Care

A 2021 cohort study in JAMA Pediatrics (N=412) found that 47% of adolescents who were receiving pharmacotherapy for obesity discontinued their medication within 12 months of transitioning to adult care, with lack of adult provider continuity being the most cited reason [9]. Weight regain after GLP-1 agonist discontinuation is well-documented: the STEP 1 extension trial showed participants regained two-thirds of lost weight within 1 year of stopping semaglutide [10]. If similar patterns apply to retatrutide, abrupt discontinuation at transition represents a clinically meaningful risk.

Electronic Health Record and Prescription Continuity

Adult providers who have not previously managed GLP-1 class or triple-agonist agents may be unfamiliar with dosing protocols, titration schedules, and monitoring requirements. Retatrutide's Phase 2 protocol used a 24-week titration from 1 mg to a target of 4, 8, or 12 mg weekly subcutaneous injection [1]. Adult providers inheriting a pediatric patient mid-titration need detailed written handoff documentation that specifies the current dose, the titration target, and the monitoring schedule for adverse effects.

Growth, Bone, and Pubertal Monitoring in Children Under 12

Skeletal and Longitudinal Growth Concerns

GLP-1 receptor agonists affect bone metabolism through multiple pathways. Preclinical data suggest GLP-1 receptors are expressed on osteoblasts and osteoclasts, and some animal studies have shown effects on bone mineral density [11]. In adult clinical trials, semaglutide did not produce clinically meaningful changes in bone density over 68 weeks [12]. Data for children under 12 are absent. Clinicians placing a pre-pubertal child on retatrutide off-label should obtain baseline dual-energy X-ray absorptiometry (DXA) and repeat it annually.

Growth velocity must be tracked at every visit. A child gaining less than 5 cm per year before the pubertal growth spurt warrants endocrinology re-evaluation of the drug's contribution.

Pubertal Development

The hypothalamic-pituitary-gonadal axis is sensitive to energy availability. Significant caloric restriction and rapid weight loss, whether from behavioral intervention or pharmacotherapy, may delay the onset of puberty [13]. Tanner staging at baseline and at each follow-up is a minimum requirement. Any unexplained delay in pubertal milestones should trigger a review of whether continued pharmacotherapy is appropriate.

Nutritional Adequacy

Children under 12 have higher nutrient-per-calorie requirements than adults due to growth demands. GLP-1-related appetite suppression combined with nausea may reduce total dietary intake below levels needed to support normal development. A registered dietitian with pediatric expertise should be part of any team managing these patients, and micronutrient panels (zinc, iron, vitamin D, B12) should be checked every 6 months [7].

Building a Transition Protocol: A Practical Framework

The following framework draws on published transition care models from the Society for Adolescent Health and Medicine, the Endocrine Society's pediatric obesity guidance, and the AAP 2023 guideline. It is designed specifically for children under 12 who are on retatrutide through a research protocol or compassionate use pathway and who will eventually move into adult endocrinology care.

Phase 1: Preparation (Ages 10 to 14, or Two to Four Years Before Transfer)

Begin transition documentation at the time therapy starts. The record should include:

• Full prescribing rationale including the clinical indication, failed prior therapies, and IRB or compassionate use approval documentation
• Baseline anthropometrics: weight, height, BMI z-score, waist circumference
• Baseline labs: fasting glucose, HbA1c, lipid panel, liver enzymes, renal function, CBC, micronutrient panel
• Baseline DXA for bone mineral density
• Tanner stage at initiation and at each follow-up
• A written titration log showing every dose change and the reason for any pause or reduction

The Endocrine Society's 2017 clinical practice guideline on obesity pharmacotherapy in pediatric patients emphasizes that any off-label use requires documented informed consent from both the parent and, where developmentally appropriate, the child [14].

Phase 2: Active Transition Preparation (Ages 14 to 17)

Beginning at age 14, the treating pediatric provider should identify a named adult endocrinologist willing to receive the patient. The Society for Adolescent Health and Medicine recommends a warm handoff: at least one joint visit where both providers are present or connected by telehealth [8].

Transition readiness should be assessed using a validated tool such as the Transition Readiness Assessment Questionnaire (TRAQ). Patients who score below 3.0 on the TRAQ's five-domain scale may need additional preparation before transfer [15].

Phase 3: Transfer and Post-Transfer Monitoring (Age 18 and Beyond)

The adult provider should receive a structured summary that includes:

• Current retatrutide dose and injection schedule
• Most recent titration date
• All adverse events including any episodes of nausea, vomiting, gastroparesis symptoms, pancreatitis concern, or injection site reactions
• Current weight trajectory and percentage body weight change from baseline
• Active comorbidities and their management status
• Outstanding monitoring items (e.g., DXA due at next visit)

Post-transfer, the first adult endocrinology visit should occur within 4 weeks of transfer. Waiting longer risks prescription lapse and the weight regain trajectory documented in GLP-1 discontinuation studies [10].

Adverse Effect Profile in the Context of Pediatric Physiology

Gastrointestinal Effects

Nausea, vomiting, and diarrhea were the most common adverse effects in retatrutide's Phase 2 adult trial. At the 12 mg maintenance dose, 54% of participants reported nausea during the titration phase, compared with 18% on placebo [1]. In children, these effects carry added risk because dehydration in a growing child can impair kidney function more rapidly than in adults.

Any pediatric patient on retatrutide should have a documented plan for managing nausea: dietary modification, dose holding rules, and a low threshold for IV hydration in urgent care settings.

Thyroid C-Cell Risk

GLP-1 receptor agonists carry an FDA boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The FDA requires this warning for all approved GLP-1 agents, and it extends to combination agonists that include GLP-1 receptor activity [4]. Children with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome must not receive retatrutide or any GLP-1-class agent. Calcitonin should be checked at baseline and annually in pediatric patients given their longer cumulative exposure potential.

Pancreatitis

Acute pancreatitis has been reported with GLP-1 receptor agonists, though causation in large trials has not been clearly established [16]. Providers managing children on retatrutide should counsel families that new-onset abdominal pain radiating to the back, especially with vomiting, is an indication to hold the drug and seek evaluation immediately.

Insurance and Access Challenges at Transition

Adult insurance plans may not cover retatrutide for a patient who was managed on a pediatric compassionate use authorization. The transition team should begin prior authorization planning no less than 6 months before formal transfer. If retatrutide remains investigational at the time of the patient's 18th birthday, the adult provider must identify whether the trial protocol allows adult continuation or whether an alternative approved therapy must be substituted.

Coverage gaps at transition are documented broadly in chronic disease management. A 2020 analysis in Health Affairs found that 24% of young adults with chronic conditions experienced a gap of 6 months or more in prescription coverage during the 24 months surrounding their 18th birthday [17]. For a drug like retatrutide where discontinuation leads to rapid weight regain, a 6-month gap is clinically consequential.

What Pediatric Providers Should Document Before Any Off-Label Use Begins

Starting retatrutide in a child under 12 outside of a formal research protocol requires careful documentation from day one, not because regulators will always audit a single practice, but because the patient's adult provider will need this information to continue safe care.

Required documentation includes the signed consent or assent form, the clinical rationale, the source of supply (compounding pharmacy or manufacturer program), and a commitment to ongoing monitoring. The FDA's guidance on off-label use and the prescribing clinician's obligations under the Federal Food, Drug, and Cosmetic Act are clear that the prescriber accepts full clinical responsibility [6].

Every 3 months, the chart should record weight, height, BMI z-score, the current dose, adverse effects, and any labs drawn. At 6 months, a formal benefit-risk reassessment should be documented. If the child is not showing at least 5% body weight reduction from baseline at 6 months, the clinical rationale for continuing therapy should be explicitly re-evaluated, consistent with the approach recommended for semaglutide in adolescents in published clinical guidance [7].